Veliparib (ABT-888)[1] is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.[2]
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.206.770 |
| Chemical and physical data | |
| Formula | C13H16N4O |
| Molar mass | 244.298 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
It inhibits both PARP1 and PARP2[1] and thereby induces synthetic lethality.It is still being evaluated for the treatment of ovarian cancer.[3]
Development
editVeliparib is being developed by AbbVie. It was derived from a prior lead compound (A 620223). The FDA awarded orphan drug status in November 2016 for NSCLC.[2]
Clinical trials
editAs of 2017, 96 clinical trials involving veliparib had been registered with the FDA.[4] It was included in the I-SPY2 breast cancer trial.[5]
Numerous phase I clinical trials are in progress.[4] Over 40 phase II clinical trials have been registered, for indications such as metastatic melanoma,[6] NSCLC, prostate cancer[7] and brain tumors associated with metastatic primary tumors.
Combination trials have evaluated veliparib in combination with doxorubicin, temozolomide, topotecan, carboplatin, paclitaxel, pemetrexed, cyclophosphamide, gemcitabine, and others.[4]
By June 2014 it was in three phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC).[8] In 2017, AbbVie reported that veliparib failed to improve outcomes in the triple-negative breast cancer and NSCLC trials.[9]
References
edit- ^ a b Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. (May 2007). "ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models". Clinical Cancer Research. 13 (9): 2728–2737. doi:10.1158/1078-0432.CCR-06-3039. PMID 17473206. S2CID 15532443.
- ^ a b "Veliparib - Abbvie". Adis Insight. Springer Nature Switzerland AG.
- ^ Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, et al. (February 2020). "Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach". Investigational New Drugs. 38 (1): 181–193. doi:10.1007/s10637-019-00867-4. PMID 31650446. S2CID 204882729.
- ^ a b c "106 Studies found for: ABT-888". ClinicalTrialsGov. U.S. National Library of Medicine.
- ^ Fox M (March 2010). "Breast cancer study aims to speed drugs, cooperation". Reuters.
- ^ Clinical trial number NCT01009788 for "A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma" at ClinicalTrials.gov
- ^ Clinical trial number NCT01576172 for "Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer" at ClinicalTrials.gov
- ^ "AbbVie takes PARP inhibitor into third phase III trial". PMLiVE. PMGroup. June 2014.
- ^ Taylor NP (20 April 2017). "AbbVie PARP inhibitor veliparib flunks two phase 3 trials". Fierce Biotech.